<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624596</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-34622</org_study_id>
    <nct_id>NCT02624596</nct_id>
  </id_info>
  <brief_title>Understanding How Ketamine Brings About Rapid Improvement in OCD</brief_title>
  <acronym>MKET</acronym>
  <official_title>NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how ketamine brings about rapid improvement in
      Obsessive-Compulsive Disorder (OCD) symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the
      economy over $2 billion annually and represents a significant public health problem. This
      study aims to build on our discovery that a potent NMDA receptor antagonist, ketamine, has
      rapid (in hours) and robust therapeutic effects in OCD. The proposed projects test the acute
      mechanism of action of ketamine at the level of molecules, circuits, and network synchrony to
      determine how NMDA receptor antagonism modifies the underlying pathology of OCD to relieve
      repetitive thoughts and behaviors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional gamma-aminobutyric acid, glutamate/glutamine levels derived from 3T Magnetic Resonance Spectroscopy</measure>
    <time_frame>up to 90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketamine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Midazolam Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for participants with OCD:

          -  age 18-65

          -  Primary diagnosis of OCD

          -  Sufficient severity of OCD symptoms

          -  ability to tolerate a treatment-free period

          -  capacity to provide informed consent

        Inclusion criteria for healthy controls:

          -  ages 18-65

          -  capacity to provide informed consent

        Exclusion criteria for participants with OCD:

          -  Psychiatric or medical conditions that make participation unsafe

          -  pregnant or nursing females

          -  concurrent use of any medications that might increase the risk of participation (e.g.
             drug interactions)

          -  presence of metallic device or dental braces

        Exclusion criteria for healthy controls:

          -  any current or lifetime psychiatric diagnosis

          -  pregnant or nursing females

          -  major medical or neurological problem

          -  presence of metallic device or dental braces
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jordan Wilson</last_name>
    <phone>650-723-4095</phone>
    <email>ocdresearch@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Filippou, MD, MBS</last_name>
    <phone>650-723-4095</phone>
    <email>ocdresearch@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Varias, MSHS</last_name>
      <phone>650-723-4095</phone>
      <email>ocdresearch@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Filippou-Frye, MD, MBS</last_name>
      <phone>650-723-4095</phone>
      <email>ocdresearch@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carolyn Rodriguez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://med.stanford.edu/profiles/carolyn-rodriguez?tab=bio</url>
    <description>Stanford Medicine Faculty Page</description>
  </link>
  <link>
    <url>http://med.stanford.edu/rodriguezlab/research/ocd-research/current-clinical-studies/mket-study.html</url>
    <description>Rodriguez Lab Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Carolyn Rodriguez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>OCD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

